As per the European Union approval, coronavirus vaccines will be given to children between five and 11 years of age.
These children will be given a lower dose of the drug than their peers aged 12 years or older, as a study has shown that their immune response is similar to that of a higher dosage.
This means that British children could have their jabs within weeks, as UK regulators could follow European Medicines Agency (EMA) recommendations.
Pfizer/BioNTech has developed the vaccine. Its official name is Comirnaty.
As coronavirus cases continue to rise across Europe, the approval of the jab is a welcome development.
New study reveals Europe could face a variety of problems “300,000 deaths and one million people in hospital”Covid, the evil one, is making havoc across the continent.
London School of Hygiene and Tropical Medicine warned that as Europe faces a new wave of Covid lockdowns, 280,000 could be hospitalized in Germany.
The UK has seen an increase in cases in school-aged children. Experts in the most affected areas of the country claim that the rise in cases can be attributed to both vaccine failures and kids.
The vaccine was administered to 1,305 children between 5 and 11 years of age who were free from any previous coronavirus infection.
The trial involved either a vaccine, or a placebo drug.
Three children from the 1,305 who were vaccinated developed Covid-19, while 16 children received placebo.
This means that the vaccine was 90.7 percent effective in preventing symptoms of Covid-19.
Experts have noted that the true rate for prevention could be as low at 67.7 percent and as high as 97.3 percent, respectively.
According to the study, the most common side effects for children were similar to those seen in the general population.
Although side effects can be mild or severe, most commonly experienced were: pain at injection site, tiredness, headaches and redness at injection site.
These symptoms usually disappear within a few days of vaccination.
Human medicines committee at the EMA said that the research showed that the vaccine’s benefits outweighed its risks.
They stated that this was especially true of children who were at high risk for severe Covid-19.
Experts are happy to announce the approval of the plan and say that children will be protected in a way that is not currently available.
Prof Russell Viner from UCL, Professor of Child and Adolescent Health: “Following FDA decisions in the USA and now in the EMA I believe it would be unlikely that our MHRA does not issue a similar license for the UK.
“A license to use a vaccine in this age-group in the UK, should it eventuate, does not necessarily mean we should vaccinate all primary-school children.
“But it would mean that children with serious other medical conditions, who are at much higher risk from Covid-19, would have access to the protection from the virus that they don’t currently have.”
We pay for stories!
Do you have a story to submit for the Central Recorder news desk